Allergic rhinitis environmental factors

Avoidance of allergen-triggering factors, through environmental control measures, is the first line of defense recommended for the management of allergic rhinitis. Environmental control measures may not completely alleviate allergy symptoms, but often symptoms improve and there may be reduced need for pharmacological intervention (63,64). 

Allergic rhinitis with a 20% incidence which is constantly increasing in relation to environmental (smog, cigarette smoke) and climatic factors is today considered a systemic disease with the nose as the shock organ [1], This trend has, consequently, resulted in an increase in social and economic expenditure on the disease arousing interest in prevention and, particularly, in specific immunosensitizing therapy administered subcutaneously or locally [2],... 

Studies of omalizumab in asthmatic volunteers showed that its administration over 10 weeks lowered plasma IgE to undetectable levels and significantly reduced the magnitude of both the early and the late bronchospastic responses to antigen challenge. Clinical trials have shown repeated intravenous or subcutaneous injection of anti-IgE MAb to lessen asthma severity and reduce the corticosteroid requirement in patients with moderate to severe disease, especially those with a clear environmental antigen precipitating factor, and to improve nasal and conjunctival symptoms in patients with perennial or seasonal allergic rhinitis. 

---